Home News About us Comitato scientifico Iscriviti Utenti Etica Contenuti Guida Faq Stage Contatti
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Alprazolam

Xanax, Frontal e altri

Bibliografia - Quali fonti bibliografiche per Alprazolam?

1. Abernethy D.R. et al., Psycopharmacol., 1983, 80, 275.

2. Almeida J.C., Grimsley E.W., Ann. Int. Med., 1996, 125, 940.

3. Altshuler L.L. et al., Am. J. Psychiatry, 1996.

4. Anderson P.O., McGuire G.G., Ann. Pharmacother., 1989, 23, 614.

5. Ballenger J.C. et al., Arch. Gen. Psychiatry, 1998, 45, 413.

6. Barbee J.G. et al., Am. J. Psychiatry, 1992, 149, 506.

7. Bigatti S.M. et al., Arthritis Rheum., 2008, 59, 961.

8. Brigg G.G. et al., Sixth ed. Lippincott Williams and Wilkins Publishing, Philadelphia, 2002, pp 30.

9. Davidson J.R., J. Clin. Psychiatry, 2004, 65 suppl. 5, 29.

10. Dawson G.W. et al., Drugs, 1984, 27, 132.

11. Dolovich L.R. et al., BMJ, 1998, 317, 839.

12. Fraser A.D. et al., J. Forens. Science, 1986, 31, 762.

13. Freighner J.P. et al., J. Am. Med. Ass., 1983, 249, 3057.

14. Gladsjo J.A. et al., J. Clin. Psychopharmacol., 2001, 21, 131.

15. Greenblatt D.J. et al., Clin. Pharmacol. Ther., 2000, 67, 335.

16. Harkness R., Bratman S., Drug-Herb-Vitamin Interaction Bible, 2000

17. Iqbal M.M. et al., Psychiatr. Serv., 2002, 53, 39.

18. Jonas J.M., Cohon M.S., J. Clin. Psychiatry, 1993, 54 (Suppl), 25, discussion 46.

19. Martindale, The Extra Pharmacopoeia, XXX ed., 1993, The Pharmaceutical Press.

20. McIntyre I.M. et al., J. For. Sci., 1994, 39, 486.

21. Med. Lett., ed. it., 1991, 11, 45.

22. Med. Lett., ed. it., 2003, Anno XXXII, N. 14.

23. Medico e Paziente, 1995, 7, 65.

24. Mikashima H. et al., Jpn. J. Pharmacol., 1987, 44, 387.

25. Ornoy A. et al., Reprod. Toxicol., 1998, 12, 511.

26. Owens M.J. et al., Pharm. Exp. Ther., 1991, 358, 349.

27. Pecknold J. et al., J. Clin. Psychopharmacol., 1994, 14, 314.

28. Perucca E., Br. J. Clin. Pharmacol., 2006, 61, 246.

29. Pharmacology, 1995, 51, 205.

30. Physicians' Desk Reference, Medical Economics Company, Inc., 2005.

31. Razavi D. et al., J. Clin. Oncol., 1993, 11, 1384.

32. Reddy J. et al., Aust. NZ J. Psychiatry, 1996, 30, 550.

33. Rickels K. et al., Am. J. Psychiatry, 1983, 140, 82.

34. Rickels K., Rynn M., J. Clin. Psychiatry, 2002, 63 suppl. 14, 9.

35. Rickels K. et al., Arch. Gen. Psychiatry, 2005, 62, 1022.

36. Roy-Byrne P. et al., Lancet, 1983, ii, 786.

37. Russell I.J. et al., Arthritis Rheum., 1991, 34, 552.

38. Schmidt P.J. et al., Arch. Gen. Psychiatry, 1993, 50, 467.

39. Schweizer E. et al., Am. J. Psychiatry, 1993, 150, 1210.

40. Sheehan D.V., J. Clin. Psychiatry, 2002, 63 suppl. 14, 17.

41. Sheikh J.I., Swales P.J., Int. J. Psychiatry Med., 1999, 29 (1), 107.

42. Tollefson G. et al., Am. J. Psychiatry, 1984, 141, 1612.

43. U.S. FDA, 2003, Code of Federal Regulations, Title 21, Volume 4, Washington, DC: U.S. Government Printing Office, pp. 21.

44. Verster J.C. et al., Neuropsychopharmacology, 2002, 27, 260.

45. Wong A.H.C. et al., Arch. Gen. Psychiatry, 1998, 55, 1033.

46. Wright C.E., Curr. Ther. Res., 1995, 56, 947.

47. Yasui N. et al., Clin. Pharmacol. Ther., 1996, 59, 514.